185 related articles for article (PubMed ID: 27885826)
1. Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma.
Boukari F; Dugourd PM; Chassang M; Mondot L; Passeron T; Lacour JP; Montaudie H
Pigment Cell Melanoma Res; 2017 Mar; 30(2):262-264. PubMed ID: 27885826
[No Abstract] [Full Text] [Related]
2. Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome.
Engel S; Luessi F; Henning B; Bittner S; Loquai C; Zipp F
Ann Oncol; 2019 Jun; 30(6):1014-1016. PubMed ID: 30911762
[No Abstract] [Full Text] [Related]
3. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
4. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
Devic P; Amini-Adle M; Camdessanché JP; Dalle S
Eur J Cancer; 2017 Jun; 78():103-104. PubMed ID: 28432982
[No Abstract] [Full Text] [Related]
5. [Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].
Kastl G
Ophthalmologe; 2019 Aug; 116(8):785-788. PubMed ID: 30357465
[TBL] [Abstract][Full Text] [Related]
6. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
7. Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment.
Kouros P; Gerding H
Klin Monbl Augenheilkd; 2016 Apr; 233(4):488-9. PubMed ID: 27116515
[No Abstract] [Full Text] [
